Abstract

BackgroundThe amount of surfactant deposited in the lungs and its overall pulmonary distribution determine the therapeutic outcome of surfactant replacement therapy. Most of the currently available methods to determine the intrapulmonary distribution of surfactant are time-consuming and require surfactant labelling. Our aim was to assess the potential of Mass Spectrometry Imaging (MSI) as a label-free technique to qualitatively and quantitatively evaluate the distribution of surfactant to the premature lamb.MethodsTwelve preterm lambs (gestational age 126-127d, term ~150d) were allocated in two experimental groups. Seven lambs were treated with an intratracheal bolus of the synthetic surfactant CHF5633 (200 mg/kg) and 5 lambs were managed with mechanical ventilation for 120 min, as controls. The right lung lobes of all lambs were gradually frozen while inflated to 20 cmH2O pressure for lung cryo-sections for MSI analysis. The intensity signals of SP-C analog and SP-B analog, the two synthetic peptides contained in the CHF5633 surfactant, were used to locate, map and quantify the intrapulmonary exogenous surfactant.ResultsSurfactant treatment was associated with a significant improvement of the mean arterial oxygenation and lung compliance (p < 0.05). Nevertheless, the physiological response to surfactant treatment was not uniform across all animals. SP-C analog and SP-B analog were successfully imaged and quantified by means of MSI in the peripheral lungs of all surfactant-treated animals. The intensity of the signal was remarkably low in untreated lambs, corresponding to background noise. The signal intensity of SP-B analog in each surfactant-treated animal, which represents the surfactant distributed to the peripheral right lung, correlated well with the physiologic response as assessed by the area under the curves of the individual arterial partial oxygen pressure and dynamic lung compliance curves of the lambs.ConclusionsApplying MSI, we were able to detect, locate and quantify the amount of exogenous surfactant distributed to the lower right lung of surfactant-treated lambs. The distribution pattern of SP-B analog correlated well with the pulmonary physiological outcomes of the animals. MSI is a valuable label-free technique which is able to simultaneously evaluate qualitative and quantitative drug distribution in the lung.

Highlights

  • Surfactant replacement therapy consists of delivering exogenous surfactant directly to the lungs of babies suffering from the Respiratory Distress Syndrome (RDS) [1]

  • According to fetal pH and Arterial Carbon Dioxide Partial Pressure (PaCO2) values, lambs were healthy before delivery

  • Surfactant treatment was associated with an increase of Arterial Oxygen Partial Pressure (PaO2), pH, Tidal Volume (VT) and Dynamic Compliance (Cdyn) and a decrease of PaCO2, Positive Inspiratory Pressure (PIP) and mean airway pressure (MAP), as expected

Read more

Summary

Introduction

Surfactant replacement therapy consists of delivering exogenous surfactant directly to the lungs of babies suffering from the Respiratory Distress Syndrome (RDS) [1]. Similar techniques based on non-radioactive tracers were further developed and have been proven useful to assess the pulmonary distribution of surfactant [11, 12]. Imaging techniques such as gamma scintigraphy or micro-PET-CT have been employed to investigate the pulmonary distribution of surfactant [2, 3]. All these techniques rely on the use of a label which is added to the surfactant. Our aim was to assess the potential of Mass Spectrometry Imaging (MSI) as a label-free technique to qualitatively and quantitatively evaluate the distribution of surfactant to the premature lamb

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call